Galera®-logo.jpg
Galera Therapeutics completes acquisition of Nova Pharmaceuticals
December 31, 2024 07:00 ET | Galera Therapeutics
Galera’s development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is...
NTRB Logo.png
Nutriband Issues Letter to Shareholders
December 31, 2024 07:00 ET | Nutriband Inc.
CEO Publishes Letter to Shareholders looking over achievements in 2024 and outlook for 2025
BioNTX StandardMed_Res.jpg
2024 Rising Stars Shine at iC³ Summit: Celebrating Progress and Setting the Stage for 2025
December 30, 2024 10:59 ET | BioNTX
DALLAS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- The 2024 Rising Stars of the life sciences and healthcare innovation sector took center stage at the iC³ Life Science Summit this year, marking another...
NTRB Logo.png
Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology
December 27, 2024 09:25 ET | Nutriband Inc.
Chinese Patent for AVERSA extended to Macao
Tevogen Logo Notified.png
Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference
December 26, 2024 12:21 ET | Tevogen Bio Inc
The JPM Healthcare Conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative...
ABIVAX_Logo-RGB.png
Abivax Announces a Change to the Composition of its Board of Directors
December 23, 2024 16:05 ET | Abivax
Abivax Announces a Change to the Composition of its Board of Directors PARIS, France, December 23, 2024, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a...
Tevogen Logo Notified.png
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference
December 23, 2024 09:38 ET | Tevogen Bio Inc
WARREN, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
fibrobiologics-logo-2022.jpg
FibroBiologics Announces $25 Million Financing
December 23, 2024 07:55 ET | Fibrobiologics, Inc.
HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
OBI Logo.jpg
浩鼎、日本頂尖醣化學衍生技術公司 GlyTech簽署二協議
December 23, 2024 04:00 ET | OBI Pharma Inc.
台灣台北, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎(4174.TWO)23日發布,與日本專注於聚醣生產和醣化學衍生技術的GlyTech, Inc.,簽署行銷和材料移轉兩項協議;日後將藉GlyTech之力,推廣日本生技製藥業採用浩鼎自主開發的GlycOBI® ADC (antibody-drug conjugate) 關鍵技術,以創造雙贏,雙方共享利益。 ...
OBI Logo.jpg
浩鼎、日本顶尖糖化学衍生技术公司 GlyTech 签署二协议
December 23, 2024 04:00 ET | OBI Pharma Inc.
台湾台北, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎(4174.TWO)23日发布,与日本专注于聚糖生产和糖化学衍生技术的GlyTech, Inc.,签署行销和材料移转两项协议;日后将借GlyTech之力,推广日本生技制药业采用浩鼎自主开发的GlycOBI® ADC (antibody-drug conjugate) 关键技术,以创造双赢,双方共享利益。 ...